Bulkow L R, Wainwright R B, Letson G W, Chang S J, Ward J I
Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, United States Department of Health and Human Services, Anchorage, AK.
Pediatr Infect Dis J. 1993 Jun;12(6):484-92. doi: 10.1097/00006454-199306000-00006.
We compared the immunogenicity of the four available Haemophilus influenzae type b (Hib) conjugate vaccines in Alaska Native infants. Three of the vaccines, Hib oligosaccharide-CRM197 (HbOC), polyribosylribitol phosphate-diphtheria toxoid (PRP-D) and polyribosylribitol phosphate-tetanus toxoid (PRP-T), were given at 2, 4 and 6 months of age, and the PRP Neisseria meningitidis outer membrane protein (PRP-OMP) conjugate vaccine was given at 2 and 4 months of age. Enrollment was largely sequential by vaccine availability beginning with HbOC and ending with PRP-T. A total of 225 infants completed the full vaccination series. Groups of infants receiving the different vaccines did not differ significantly by sex, ethnicity, degree Alaska Native or age at vaccination. The only vaccine that induced a response with the first 2-month dose was PRP-OMP; 91% of infants had > or = 0.15 micrograms/ml and 57% had > or = 1.0 microgram/ml of anti-PRP antibody by 4 months of age. After two doses it also remained the most immunogenic. After the full three vaccine series, trials that requires cough of 21 days is excessively restrictive.
我们比较了四种现有的b型流感嗜血杆菌(Hib)结合疫苗在阿拉斯加原住民婴儿中的免疫原性。其中三种疫苗,即Hib寡糖-CRM197(HbOC)、多聚核糖磷酸-白喉类毒素(PRP-D)和多聚核糖磷酸-破伤风类毒素(PRP-T),在2、4和6月龄时接种,而PRP-脑膜炎奈瑟菌外膜蛋白(PRP-OMP)结合疫苗在2和4月龄时接种。入组基本上按照疫苗可获得情况依次进行,从HbOC开始,以PRP-T结束。共有225名婴儿完成了全程疫苗接种。接受不同疫苗的婴儿组在性别、种族、阿拉斯加原住民程度或接种时的年龄方面没有显著差异。唯一在2月龄首剂接种后诱导出反应的疫苗是PRP-OMP;到4月龄时,91%的婴儿抗PRP抗体水平≥0.15微克/毫升,57%的婴儿抗PRP抗体水平≥1.0微克/毫升。两剂接种后,它仍然是免疫原性最强的。在完成全程三剂疫苗接种后,要求咳嗽21天的试验限制过度。